Ground broken on Lek's new high-tech centre for the production of biosimilars
Lendava, 11 December - The foundation stone was laid in Lendava on Monday for a new high-tech centre for the production of biosimilars by pharma company Lek. The state-backed US$ 400 million-plus investment, hailed at the event by the CEO of Lek's Swiss owner Sandoz, Richard Saynor, and PM Robert Golob, is expected to be ready by 2026 and generate around 300 jobs.
Lendava
A ceremony marking the start of construction of Lek's new high-tech centre for the production of biosimilars.
Photo: Daniel Novakovič/STA
Lendava
PM Robert Golob (left) at a ceremony marking the start of construction of Lek's new high-tech centre for the production of biosimilars.
Photo: Daniel Novakovič/STA
Lendava
A ceremony marking the start of construction of Lek's new high-tech centre for the production of biosimilars.
Photo: Daniel Novakovič/STA
Lendava
A ceremony marking the start of construction of Lek's new high-tech centre for the production of biosimilars.
Photo: Daniel Novakovič/STA
Lendava
PM Robert Golob (left) at a ceremony marking the start of construction of Lek's new high-tech centre for the production of biosimilars.
Photo: Daniel Novakovič/STA
Lendava
PM Robert Golob speaks at a ceremony marking the start of construction of Lek's new high-tech centre for the production of biosimilars.
Photo: Daniel Novakovič/STA
Lendava
PM Robert Golob (right) at a ceremony marking the start of construction of Lek's new high-tech centre for the production of biosimilars.
Photo: Daniel Novakovič/STA
The rest of this news item is available to subscribers.
The news item consists of 2.370 characters (without spaces) or 441 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.